ALB and sarcopenia: Furthermore, we assessed whether frailty and comorbidities, tumor complexity and other parameters, such as ASA score, single kidney, albumin level or sarcopenia, are determining factors for the therapeutic strategy patients and clinicians choose as treatment for renal masses.